Senti Biosciences, Inc. (SNTI)
NASDAQ: SNTI · Real-Time Price · USD
2.200
-0.010 (-0.45%)
At close: Jul 3, 2025, 1:00 PM
2.260
+0.060 (2.73%)
After-hours: Jul 3, 2025, 4:55 PM EDT
Senti Biosciences Stock Forecast
Stock Price Forecast
The 2 analysts that cover Senti Biosciences stock have a consensus rating of "Strong Buy" and an average price target of $8.5, which forecasts a 286.36% increase in the stock price over the next year. The lowest target is $5 and the highest is $12.
Price Target: $8.5 (+286.36%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Senti Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 | Strong Buy | Maintains | $12 | +445.45% | Jun 12, 2025 |
| Laidlaw & Co. | Laidlaw & Co. | Strong Buy Initiates $5 | Strong Buy | Initiates | $5 | +127.27% | Jun 6, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 | Strong Buy | Maintains | $12 | +445.45% | May 2, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $10 → $12 | Strong Buy | Maintains | $10 → $12 | +445.45% | Dec 4, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +354.55% | Dec 2, 2024 |
Financial Forecast
Revenue This Year
2.04M
Revenue Next Year
5.10M
from 2.04M
Increased by 150.00%
EPS This Year
-2.39
from -12.03
EPS Next Year
-1.26
from -2.39
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2028 | 2029 |
|---|---|---|---|---|
| High | 2.1M | 5.3M | n/a | |
| Avg | 2.0M | 5.1M | n/a | |
| Low | 2.0M | 4.9M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2028 | 2029 |
|---|---|---|---|---|
| High | - | 157.4% | - | |
| Avg | - | 150.0% | - | |
| Low | - | 140.2% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2028 | 2029 |
|---|---|---|---|---|
| High | -2.46 | -1.30 | -5.01 | |
| Avg | -2.39 | -1.26 | -4.87 | |
| Low | -2.29 | -1.22 | -4.67 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2028 | 2029 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.